BIRB.0796, a potent p38MAPK inhibitor60, reduces the synthesis of the pleiotropic cytokine oncostatin M (OSM)-induced vascular endothelial growth factor (VEGF)61, suggesting its therapeutic potential in GC. Here, VEGFA is linked to gastric cancer.